Latest Headlines

  1. New $400,000 Grant Supports EverythingALS.org And Mass General Hospital (MGH) To Develop NeuroLens, A Digital Diagnostics Technology Initiative For Early Detection Of Amyotrophic Lateral Sclerosis (ALS) 8/22/2023

    EverythingALS today announced it has received $400,000 from ALS Finding a Cure and The ALS Association to support studies for the identification of early digital diagnostic markers of ALS. 

  2. Thermo Fisher Scientific Introduces New Chromosomal Microarray With Two-Day Turnaround Time To Increase Lab Productivity 8/22/2023

    Thermo Fisher Scientific, the world leader in serving science, today announced the launch of a new chromosomal microarray designed to improve cytogenetic research lab productivity, efficiency and profitability with an industry-leading two-day turnaround time.

  3. STARLIMS Acquires Labstep, Expanding Its Portfolio Across R&D Through Product Commercialization 8/22/2023

    Today STARLIMS, a leading provider of enterprise informatics solutions, announces the expansion of its solution suite through the strategic acquisition of Labstep, a cutting-edge, R&D Electronic Laboratory Notebook (ELN).

  4. Biodesix Announces Presentation Of New Nodify XL2 Data At AABIP Conference Highlighting Increased Proportion Of Biopsies Diagnosing Cancer 8/22/2023

    Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that a new analysis from the post-market, prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2 Test NCT03766958) will be presented at the 6th Annual Conference of the American Association for Bronchology and Interventional Pulmonology (AABIP).

  5. Mainz Biomed Announces Live Launch Of ColoAlert® With testDNA Laboratory In Poland 8/22/2023

    Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the commercial launch of ColoAlert® in Poland, made possible through a strategic collaboration with testDNA Sp. z o. o. Sp. K (“testDNA”).

  6. Geneseeq Gains CE Marks For NGS-Based Test Kits For Solid Tumors And Hematological Cancer 8/22/2023

    Geneseeq Technology Inc. has announced that three of our next-generation sequencing (NGS)-based cancer genetic testing kits, GENESEEQPRIME NGS Tumor Gene Detection Kit (GeneseeqPrime ™), GENESEEQ Homologous Recombination Deficiency Detection Kit (GeneseeqPrime™ HRD), and GENESEEQ Blood Cancer Gene Detection Kit (Hemasalus™ DNA/Hemarna™ RNA), have obtained the European Union's CE Mark approval.

  7. HealthTrackRx Expands National Footprint With Los Angeles Area PCR Laboratory 8/22/2023

    HealthTrackRx, the nation's premier molecular diagnostic testing laboratory, today announced the opening of its latest high-throughput lab in Los Angeles, CA.

  8. Avalon’s Laboratory Services MSO Announces Expansion Into Arizona 8/21/2023

    Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”) is opening a new laboratory, Veritas Laboratories LLC (“Veritas”), in Scottsdale, Arizona. Avalon owns a 40% interest in LSM.

  9. Boekel Scientific Introduces New Centrifuge Product Line 8/21/2023

    Boekel Scientific introduces a new product line that consists of 4 families of centrifuges: economy, general purpose, STAT, and Blood Bank.

  10. Satio Partners With BARDA DRIVe To Develop A Novel Patch-Based Ebolavirus Diagnostic 8/18/2023

    Satio is pleased to announce a contract awarded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to develop a novel, single-use, rapid ebolavirus diagnostic.